CLINICAL_TRIALS
trial_result
· 2022-09-08
Clinical Trial Update: A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis [Phase 2]
Summary
Phase 2 open-label and crossover study investigating belumosudil for idiopathic pulmonary fibrosis has completed and results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Kadmon Corporation, LLC | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2022-09-08